Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cynthia Juarez

Nurse Practitioner, Obstetrics & Gynecology Arcadia, CA Nurse Practitioner

NPI 1730218231 CMS profile 10449639

601 Las Tunas Dr, 101, Arcadia, CA 91007

Open in the dashboard

General payments

$4,284

188 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cynthia Juarez of Arcadia, CA is reported in the CMS Open Payments database as having received $4,284 across 188 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $714 33
2024 General $642 26
2023 General $685 36
2022 General $761 42
2021 General $1,483 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cynthia Juarez
  • Nurse Practitioner, Obstetrics & Gynecology median
  • Middle half of Nurse Practitioner, Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Cynthia Juarez were reported at $714. Among 1,030 Nurse Practitioner, Obstetrics & Gynecology profiles paid that year, the median was $151 and the middle half received between $51 and $371.

Show as a table
Year Cynthia Juarez Nurse Practitioner, Obstetrics & Gynecology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,483 $135 $40–$338 $132
2022 $761 $143 $45–$386 $149
2023 $685 $153 $54–$411 $160
2024 $642 $140 $45–$326 $164
2025 $714 $151 $51–$371 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,377 88 payments
  2. Sumitomo Pharma America, Inc. $365 20 payments
  3. Shield Therapeutics Inc $333 16 payments
  4. Pfizer Inc. $230 10 payments
  5. Astellas Pharma US Inc $189 5 payments
  6. Myovant Sciences Inc. $178 16 payments
  7. Millicent US Inc $131 6 payments
  8. Mayne Pharma Inc. $122 9 payments
  9. Exeltis, USA Inc. $121 7 payments
  10. Sage Therapeutics, Inc. $104 4 payments
  11. Other $133 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,193 187 payments
  2. Education $91 1 payment
Products named General payments · program years 2021–2025
  1. ORILISSA $1,248 49 payments
  2. ORIAHNN $540 14 payments
  3. MYFEMBREE Hormone Therapy $481 33 payments
  4. LO LOESTRIN FE $480 28 payments
  5. ACCRUFER $333 16 payments
  6. MAVYRET $218 6 payments
  7. PREMARIN $176 8 payments
  8. MYFEMBREE Genitourinary (Sexual Health);Womens Health $128 5 payments
  9. INTRAROSA $108 5 payments
  10. ZURZUVAE $104 4 payments
  11. Other $840 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

60

Median for Nurse Practitioner: 389

Drug cost

$8,135

Median for Nurse Practitioner: $21,885

Branded share of claims

46.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Premarin Estrogens, Conjugated Brand 14 $6,057
Estradiol Generic 15 $1,699
Acyclovir Generic 17 $215
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 14 $163

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $88
  • PFIZER INC. $51
$139 — —
Veozah
  • Astellas Pharma US Inc $98
$98 — —
SLYND
  • Exeltis, USA Inc. $46
$46 — —
ABRYSVO
  • PFIZER INC. $25
$25 — —
FEMRING
  • MILLICENT US INC $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

188 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Obstetrics & Gynecology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record